News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Present at the 2015 Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 5, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mike Raab , Chief Executive Officer, will present an overview of the company at the Wedbush PacGrow
View HTML
Toggle Summary Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City
Tenapanor development plans will be presented along with new data demonstrating sustained response in IBS-CDevelopment plans will be presented for RDX022, Ardelyx's next generation potassium binder for the treatment of hyperkalemiaIND filing targeted in 2H16 for RDX009, a TGR5 agonist that stimulates local secretion of GLP-1 and GLP-2 in the gutWebcast Today at 8:00 am EDT
View HTML
Toggle Summary Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015
FREMONT, Calif. , June 30, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that the Company will host its inaugural R&D Day on July 14, 2015 , from 8:00 a.m.- 1:00 pm EDT
View HTML
Toggle Summary Ardelyx to Present at the 2015 JMP Securities Life Sciences Conference
FREMONT, Calif. , June 16, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Mark Kaufmann , Chief Financial Officer, will present an overview of the company at the JMP
View HTML
Toggle Summary Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
Ardelyx to Pursue an Accelerated 505b(2) Regulatory Pathway for RDX022 with Initiation of Phase 3 Program to Begin as Early as Second Half 2016Conference Call and Webcast Today at 8:30am ET
View HTML
Toggle Summary Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds
Ardelyx to Initiate a Phase 3 Clinical Program in IBS-C Patients in the Fourth Quarter of 2015Conference Call and Webcast Today at 8:30 am ET
View HTML
Toggle Summary Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
FREMONT, Calif. , May 19, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically
View HTML
Toggle Summary Ardelyx Reports First Quarter 2015 Financial Results
FREMONT, Calif. , May 12, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced financial results for the first quarter ended March 31, 2015 .
View HTML
Toggle Summary Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria
-- Conference Call and Webcast Today at 5:00 p.m. ET --
View HTML
Toggle Summary Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors
FREMONT, Calif. , April 20, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Annalisa Jenkins , MBBS , MRCP, has joined the Company's Board of Directors. Dr.
View HTML